Developing a new medicinal product is a long and complex process, from modelling of the new compound through to the granting of Marketing Authorisation (MA).
Once a new drug has been developed, it has to be confirmed that it is effective and safe by using protocols involving substantial numbers of patients.
In the performance of clinical trials, the participating subjects undergo many examinations and a correspondingly large number of laboratory tests have to be performed. This is why Biomnis has developed a special Clinical Trial Department.
Biomnis relies on the experience of its 45 pathologists whose experience and up to date knowledge of new technologies enable them to meet the special requirements of clinical trials.
Biomnis has two high-volume, state-of-the-art multidisciplinary premises which ensure that clinical trial requirements—in terms of quality and turnaround time as well as regulatory constraints—are fulfilled.
Testing for clinical trials is governed by strict quality criteria since Marketing Authorisation applications are particularly scrupulously assessed by the health authorities. Biomnis can meet all the specific requirements in matters such as the record traceability, the archiving of raw data, electronic data transfer and support for auditing procedures as well as complementary services such as Biomnis serum library.